Sirtex Medical to Distribute Surefire Medical, Inc.'s Innovative Infusion System in Australia and Asia Pacific Markets

SYDNEY and WESTMINSTER, Colo., June 20, 2013 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) and US-based Surefire Medical today announced a sales and marketing partnership to distribute Surefire's range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.

The agreement will see Sirtex exclusively distribute the Surefire Medical range of products in the company's rapidly growing Asia Pacific markets including Australia.

Sirtex reported a 30 per cent growth in dose sales of its targeted radiation treatment for liver cancer in the Asia Pacific region at the end of the third quarter ended 31 March 2013.

Rapidly growing Surefire Medical has received regulatory approval in the U.S., Europe, Canada and New Zealand. Its first-in-class infusion systems are used by numerous top-ranked cancer centers and hospitals in these markets.

The Surefire Infusion System has been designed to enhance the accuracy and delivery of drugs directly to tumors. Surefire products use a patented microcatheter with an expandable tip. When deployed, the tip dynamically responds to flow conditions to enable more of the embolic agent to reach the intended destination while reducing non-target delivery compared to traditional infusion systems.

The ability to more safely and efficiently deliver embolic agents directly to target tumors marks a significant advance in radiation oncology procedures and in the treatment of liver cancer.

Sirtex Medical Asia Pacific Chief Executive Officer Dr. Burwood Chew said, "Sirtex is constantly looking for new ways to help our customers improve the outcomes of their patients with liver cancer. We believe this distribution partnership will allow us to provide interventional radiologists and oncologists with a wider range of options that may potentially lead to improved patient outcomes, which is our shared goal."

Surefire Medical CEO Jim Chomas said, "A growing body of positive clinical evidence and the enthusiasm of our increasing user base at hospitals worldwide continue to prove the efficacy of the Surefire line of infusion systems. The agreement with Sirtex enables our companies to jointly pursue more effective treatment for the rising worldwide incidence of liver cancer."

For further information please refer to www.surefiremedical.com and sirtex.com

SIR-Spheres^® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

SOURCE Surefire Medical, Inc.